Abstract
Background Patient age is the most salient clinical indicator of risk from COVID-19. Age-specific distributions of known SARS-CoV-2 infections and COVID-19-related deaths are available for many regions. Less attention has been given to the age distributions of serious medical interventions administered to COVID-19 patients, which could reveal sources of potential pressure on the healthcare system should SARS-CoV-2 prevalence increase.
Methods We analysed 97,957 known SARS-CoV-2 infection records for Ontario, Canada, from 23 January 2020 to 26 November 2020 and estimated the age distributions of hospitalizations, Intensive Care Unit admissions, intubations, and ventilations. We quantified the probability of hospitalization given known SARS-CoV-2 infection, and of survival given COVID-19-related hospitalization.
Results The distribution of hospitalizations peaks with a wide plateau covering ages 54–90, whereas deaths are concentrated in very old ages. The estimated probability of hospitalization given known infection reaches a maximum of 30.9% at age 80 (95% CI 28.0%–33.9%). The probability of survival given hospitalization is near 100% for adults younger than 40, but declines substantially after this age; for example, a hospitalized 54-year-old patient has a 91.5% chance of surviving COVID-19 (95% CI 87.0%–94.9%).
Conclusions Ontario’s healthcare system has not been overstretched by COVID-19 thanks to wide-spread infection control efforts, yet the probability of survival given hospitalization for COVID-19 is lower than is generally perceived for patients over 40. As prevalence continues to increase during this most recent wave of infection, healthcare capacities are at risk of being exceeded. Survival of individuals in the broad age range requiring acute care could decrease, potentially expanding the distribution of COVID-19-related deaths toward younger ages.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
DJDE, BMB, and JD were funded by the Natural Sciences and Engineering Research Council of Canada, the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University, and the Public Health Agency of Canada.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received ethics approval from the Health Sciences Research Ethics Board at the University of Toronto.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated data and revised text to reflect the current situation in Ontario.
Data Availability
Data and source code for all analyses will be provided in an Open Science Framework repository upon publication of this manuscript.
Abbreviations
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- KI
- Known Infection
- COVID-19
- Coronavirus Disease 2019
- ICU
- Intensive Care Unit
- CCM
- Case and Contact Management
- OLIS
- Ontario Laboratories Information System
